Stock AnalizAlcon Inc. ALC
Ophthalmic Goods · IPO 2019 · data as of November 13, 2026
Alcon Inc. (ALC) is a healthcare company listed in the US with a market value of about $37.0B. In the twelve months to September 30, 2026 it had revenue of $11.0B and net income of $666M, a net margin of 6.1%.
Its overall Stock Analiz score is 2.0 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: a P/E of 54.4, a price to free cash flow of 22.2, 5-year revenue growth of 9% a year, a 5-year average ROIC of 3%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 53% below the current price.
Score: 2.0 / 5
Checks passed
- 3-year free cash flow growth above 10% a year
- 5-year revenue growth above 8% a year
- Profitable 5 years in a row
- More cash than debt, or low debt to equity
- Positive free cash flow
- Interest covered more than 5 times
- Liabilities below 60% of assets
- Pays a dividend
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.0B | $10.4B | $9.9B | $9.5B | $8.7B | $8.3B | $6.8B | $7.5B | $7.2B | $6.8B | $7.2B |
| Net income | $666M | $980M | $1.0B | $974M | $335M | $376M | -$531M | -$656M | -$227M | $256M | $2.2B |
| Free cash flow | $1.7B | $1.7B | $1.6B | $730M | $581M | $645M | $344M | $367M | $616M | $803M | $2.1B |
| EPS (diluted) | $1.36 | $1.96 | $2.04 | $1.95 | $0.67 | $0.75 | $-1.06 | $-1.31 | $-0.45 | $0.51 | $4.42 |
| Net margin | 6.1% | 9.4% | 10.3% | 10.3% | 3.8% | 4.5% | -7.8% | -8.7% | -3.2% | 3.8% | 30.8% |
| ROIC | — | 4.3% | 4.4% | 3.2% | 2.0% | 2.2% | -1.8% | -0.7% | -0.8% | -0.3% | 29.6% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 16 analysts is $81.46, 10% above the current price; targets range from $63.00 to $103.00; the consensus rating is “Buy”; expected EPS is $3.48 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Alcon’s P/E ratio?
About 54.4, based on the last twelve months of diluted earnings per share (forward P/E about 21.9).
Is Alcon stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 53% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Alcon pay a dividend?
Yes. The dividend yield is about 0.49%, and it has paid dividends for 6 years in our data.
Is Alcon a good stock to buy?
We do not give buy or sell advice. Alcon scores 2.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.